---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-023196"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:49:46.619015+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Esperion closes $75M acquisition of Corstasis, adds Enbumyst nasal spray

## Summary
- Closed acquisition of Corstasis Therapeutics for $75M cash upfront; up to $180M in milestones and royalties.
- Acquired Enbumyst (bumetanide nasal spray), first FDA-approved nasal spray loop diuretic for edema.
- Entered $25M term loan amendment and $50M royalty sale to Athyrium to partially finance the deal.
- Enbumyst approved Sept 2025; Esperion plans commercial infrastructure to drive adoption.
- Acquisition supports Vision 2040, diversifies cardiometabolic portfolio, expected revenue growth.

## SEC filing metadata
- accession: 0001628280-26-023196
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828026023196/0001628280-26-023196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828026023196/espr-20260402.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-023196
- JSON: https://secwatch.observer/filing/0001628280-26-023196.json
- Plain text: https://secwatch.observer/filing/0001628280-26-023196.txt

## Source-grounded claims
- claim_id: 4173be2c5bdfcc4ef521b79f45ac89a5a59cb40d
  claim: Esperion Therapeutics, Inc. incurred term loan of $25,000,000 with GLAS USA LLC and GLAS Americas LLC, collectively, as the administrative agent for the lenders.
  evidence_excerpt: The First Amendment amends that certain Credit Agreement, dated as of December 13, 2024 (the “Existing Credit Agreement” and as amended by the Amendment, the “Credit Agreement”), by and among the Company, the Administrative Agent and the lenders party thereto. The Amendment, among other things, provides for the incurrence of additional term loans in an aggregate principal amount of $25,000,000 (the “First Amendment Term Loans”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828026023196/0001628280-26-023196-index.htm
- claim_id: 82dade3cdd71e9f0156fefb69b770734bc32dd7a
  claim: Esperion Therapeutics, Inc. completed an acquisition involving Corstasis Therapeutics Inc. for The aggregate up-front consideration for the transactions contemplated by the Merger Agreement (the “Transactions”) was $75,000,000 in cash, subject to customar (closed 2026-04-02).
  evidence_excerpt: On March 2, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Corstasis Therapeutics Inc., a Delaware corporation (“Corstasis”), Cirrus Transaction Subsidiary, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”) and certain other parties described therein. Pursuant to the Merger Agreement, on April 2, 2026, the Company completed the merger of Corstasis with and into Merger Sub, with Corstasis surviving the merger as a wholly owned subsidiary of the Company (the “Merger”). The aggregate up-front consideration for the transactions contemplated by the Merger Agreement (the “Transactions”) was $75,000,000 in cash, subject to customary adjustments and a post-closing purchase price adjustment. In addition, the equityholders of Corstasis are entitled to receive: (i) milestone payments up to an aggregate amount equal to $180,000,000 if certain regulatory approval or commercial sales milestones are achieved and (ii) r
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828026023196/0001628280-26-023196-index.htm
- claim_id: 3a9eb7f9e3d40fa76a90f5aff37511e94d4f5ef4
  claim: Esperion Therapeutics, Inc. entered into First Amendment to Credit Agreement with GLAS USA LLC and GLAS Americas LLC, collectively, as the administrative agent (effective 2026-04-02).
  evidence_excerpt: On April 2, 2026 (the “Closing Date”), Esperion Therapeutics, Inc. (the “Company”) entered into the First Amendment to Credit Agreement (the “Amendment”), by and among the Company, as the borrower, the lenders party thereto and GLAS USA LLC and GLAS Americas LLC, collectively, as the administrative agent for the lenders (the “Administrative Agent”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828026023196/0001628280-26-023196-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.